Calypte(765254) scheint aufzuerstehen!
Thread abonnieren
|
--button_text--
interessant
|
|
witzig
|
|
gut analysiert
|
|
informativ
|
2
Moderation
Zeitpunkt: 27.06.07 13:47
Aktion: Forumswechsel
Kommentar: falsche Forum
Zeitpunkt: 27.06.07 13:47
Aktion: Forumswechsel
Kommentar: falsche Forum
Optionen
| Antwort einfügen |
| Boardmail an "Biomedi" |
|
Wertpapier:
Calypte Biomedical
|
0
morgen werden sie dafür dann voller panik in d werfen...
Time & Sales most recent next page
Rec. Time Action Price Volume
12:56:30 PM Trade 0.175 8900
12:56:12 PM Trade 0.175 6100
12:56:10 PM Trade 0.18 10000
12:56:02 PM Trade 0.175 16415
12:42:40 PM Trade 0.175 3800
12:42:38 PM Trade 0.175 3800
12:42:38 PM Trade 0.175 3900
12:42:36 PM Trade 0.175 3800
12:30:40 PM Trade 0.175 333
12:23:24 PM Ask 0.18 5000
12:23:24 PM Trade 0.175 20300
12:23:20 PM Trade 0.18 5000
12:23:16 PM Bid 0.175 5000
12:23:16 PM Ask 0.181 5000
11:50:50 AM Trade 0.18 2000
11:31:54 AM Trade 0.18 5000
11:18:30 AM Trade 0.18 2000
11:07:54 AM Trade 0.18 20000
11:01:36 AM Trade 0.18 100
10:44:32 AM Bid 0.18 5000
10:36:12 AM Trade 0.18 10000
10:36:06 AM Ask 0.185 5000
10:30:06 AM Trade 0.175 333
10:26:44 AM Ask 0.18 5000
10:22:44 AM Trade 0.18 15000
10:22:38 AM Ask 0.185 5000
10:12:32 AM Ask 0.18 5000
10:12:28 AM Trade 0.18 5000
10:12:28 AM Trade 0.18 13500
10:12:28 AM Bid 0.175 5000
10:00:54 AM Trade 0.18 36500
10:00:54 AM Bid 0.18 5000
10:00:48 AM Ask 0.185 5000
9:59:40 AM Trade 0.18 1000
9:59:30 AM Ask 0.18 5000
9:59:28 AM Bid 0.175 5000
9:59:14 AM Trade 0.18 13500
9:47:24 AM Trade 0.18 20000
9:43:44 AM Trade 0.18 12315
9:39:56 AM Ask 0.185 5000
9:32:42 AM Trade 0.18 6000
9:31:34 AM Bid 0.18 5000
9:31:28 AM Trade 0.182 6000
9:30:08 AM Trade 0.185 500
9:30:08 AM Trade 0.185 2500
9:30:08 AM Ask 0.19 5000
most recent next page
1:05:04 PM EDT - Monday, October 29, 2007 - data is real-time
Optionen
0
Geneva Office to Expand Company’s Relationships with International Organizations
And to Lead Marketing Efforts of Diagnostic Products to Europe, Central Asia and French-speaking Africa
PORTLAND, Ore.--(BUSINESS WIRE)--Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has established a branch office in Geneva, Switzerland to expand the Company’s relationships with International Organizations, as well as market its diagnostic tests to Europe, Central Asia and French-speaking Africa. The Company named experienced executives Khatuna Janjalia, President and Kartlos Edilashvili, Vice President of the Geneva Branch Office.
“We believe that a regional presence on the ground is a key component in reaching these new markets, which represent attractive opportunities for Aware®,” said Roger I. Gale, Chairman and Chief Executive Officer of Calypte. “The Geneva Branch Office will also provide policy and technical advisory services for the Company, liaising with external counterparts in international NGO, humanitarian organizations and multilaterals based out of Geneva.”
Ms. Janjalia joins Calypte from the Audit Control and Expertise Group (ACE), where she was Head of the Department for East Europe, South Caucasus and Central Asia. While there, she established and strengthened affairs with partner companies in the countries within Eastern Europe, South Caucasus and Central Asia. She also originated structured trade and commodity finance. ACE serves major international/local banks, trading companies and suppliers of manufactured goods and equipment in the field of international commodity risk management. As a credit enhancement organization, it provides third-party asset management, quality assurance and inspection services. Previously, she was a Senior Representative for International and Media Relations of the World Agency of Planetary Monitoring and Earthquake Risk Reduction (WAPMERR). She also held position as Consul of the Embassy of Georgia to Switzerland, the Counsellor of the Permanent Mission of Georgia to the UN Office and other International organizations at Geneva.
“I am excited to join Calypte where I expect to use my relationships to help market Aware® to governments and international organizations,” said Ms. Janjalia. “Geneva represents the ideal location, as many of the organizations involved in global healthcare, such as the Global Fund, UNAIDS and the World Health Organization (WHO) are based here. Geneva is where all countries have diplomatic representations to these organizations as well. With the need for accurate cost-effective treatment in developing countries, I look forward to helping Calypte play an important role in the prevention and treatment of HIV.”
Mr. Edilashvili joins Calypte from WAPMERR, where he was a senior technical adviser. Previously, he was the First Secretary for the Permanent Mission of Georgia to the U.N. Office and other International organizations at Geneva.
Optionen
| Antwort einfügen |
| Boardmail an "kinu" |
|
Wertpapier:
Calypte Biomedical
|
0
0
ein hoch auf GALE und alles, was er "geschafft" hat.
immerhin hat er es geschafft, euch eine illusion zu verkaufen und euch damit euer geld im namen der ethink, moral und menschlichkeit wegzunehmen.
Optionen
0
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 10, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that its Chinese manufacturing subsidiary, Beijing Marr Bio-pharmaceutical Co., Ltd., ("Beijing Marr"), has received a permit to manufacture medical devices issued by the Beijing branch of the Chinese Food and Drug and Administration. The manufacturing permit enables the facility to manufacture in vitro diagnostic tests for the domestic Chinese market once specific product approval is received. The permit is required before Beijing Marr can sell an approved product within the country. Beijing Marr is currently awaiting approval from the China State Food and Drug Administration (SFDA) to distribute and sell Calypte's Aware(TM) HIV-1/2 OMT rapid diagnostic test within China.
Beijing Marr, a joint venture between Calypte and a Marr Group subsidiary was established to manufacture Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and international markets. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable to that of U.S. FDA approved blood based laboratory HIV EIA tests.
Roger I. Gale, Calypte's President and Chief Executive Officer, commented, "Coming on the heels of the recent ISO 13485 Certification of Beijing Marr's manufacturing facility, this permit is another significant milestone that brings us much closer to our objective of manufacturing and marketing our rapid test product for the Chinese market."
David K. Harris, Chief Executive Officer of Beijing Marr stated, "This permit is required because the State Food and Drug Administration moved regulatory oversight for HIV tests from the Drug Division to the Medical Device Division. Our team has been working diligently to obtain this permit to ensure that we will be permitted to manufacture our Aware(TM) HIV-1/2 OMT test once it has been approved for sale in China."
About The Marr Group:
The Marr Group is a private group of companies having a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS.
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
Optionen
| Antwort einfügen |
| Boardmail an "Sylvia" |
|
Wertpapier:
Calypte Biomedical
|
0
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 23, 2008--Calypte Biomedical Corporation (OTCBB:CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today announced it has entered into a $8.0 million common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-based institutional investor. The Company may sell up to $8.0 million of its common stock to Fusion Capital from time to time over a 24-month period after the Securities and Exchange Commission (SEC) has declared effective the registration statement related to the transaction. The proceeds will be used to further the commercialization of the Company's Aware(TM) HIV-1/2 Rapid diagnostic tests, develop new diagnostic tests and for general corporate purposes.
Under the agreement, the Company has the right to sell shares of common stock to Fusion Capital from time to time in amounts between $100,000 and $1.0 million, depending on certain conditions, for up to $8.0 million of total funds. The purchase price of the shares will be based on the prevailing market prices of the Company's shares at the time of sale without any fixed discount, and the Company will control the timing and amount of any sales of shares to Fusion Capital. There are no negative covenants, restrictions on future financings, penalties or liquidated damages in the agreement. A more detailed description of the transaction, as well as the agreement, is set forth in the Company's Report on Form 8-K filed today with the SEC which should be reviewed carefully in conjunction with this press release.
"We are very pleased to enter into this $8.0 million funding agreement with Fusion Capital, a respected institutional fund that has been investing in technology and health care companies for over eight years," said Roger I. Gale, CEO of Calypte. "The agreement, as a complement to funding potentially available to us from other sources, provides the Company with the flexibility to help us grow our rapid HIV diagnostic testing business in large developing markets as well as in the U.S."
About Calypte Biomedical Corporation:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
About Fusion Capital
Fusion Capital Fund II, LLC is an institutional investor based in Chicago, Illinois with a fundamental investment approach. Since 1999, Fusion Capital has invested in a wide range of companies and industries emphasizing life sciences, energy and technology companies. Its investments range from special situation financing to long-term strategic capital.
Forward-Looking Statements
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
Optionen
| Antwort einfügen |
| Boardmail an "kague" |
|
Wertpapier:
Calypte Biomedical
|
0
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 24, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that the Chinese State Food and Drug Administration ("SFDA") has notified Calypte's Chinese manufacturing subsidiary, Beijing Marr Bio-pharmaceutical Co., Ltd., ("Beijing Marr") that the technical review of its Aware(TM) HIV-1/2 OMT rapid oral test product application has been completed. Pending the SFDA's review of conformity to product standard documents and labeling to applicable regulations, the application will progress to the concluding administrative approval.
Roger I. Gale, Calypte's President and Chief Executive Officer, stated, "This is a major milestone in a long and difficult approval process. We are extremely pleased that the SFDA has determined that our scientific data has met their criteria, and that we are now moving into the final phase of the registration process. We believe that in meeting the technical standards established by the SFDA, we have demonstrated to them the high quality of our product."
Dr. Ronald W. Mink, Calypte's Chief Science Officer, commented, "The technical review is considered the most challenging and lengthy portion of the SFDA review process, and is the penultimate milestone in the approval process. We are absolutely delighted that we have overcome what is arguably the highest hurdle in the approval process, and are ready to move into the final administrative stage."
David K. Harris, Beijing Marr's Chief Executive Officer stated that, "The notice from the SFDA is of paramount importance and indicates that the substantive content of the application and the technology itself have met with the acceptance of the SFDA and are acceptable for the Chinese market. Nearing the end of an arduous approval process, we are very proud to see this recognition of years of hard work in developing the Aware(TM) HIV-1/2 OMT product."
Calypte operates in China through Beijing Marr, a joint venture between Calypte and the Marr Group established to manufacture Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and international markets. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable to that of U.S. FDA approved blood based laboratory HIV EIA tests.
About The Marr Group:
The Marr Group is a private group of companies having a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS.
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
Optionen
| Antwort einfügen |
| Boardmail an "Sylvia" |
|
Wertpapier:
Calypte Biomedical
|
0
PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 30, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today launched its latest new product, Aware Messenger(TM), an oral fluid sample collection device for collecting high-quality oral fluid specimens for high-throughput laboratory testing.
"We developed the Aware Messenger(TM) device in response to inquiries from several of our U.S. and international customers who requested a safe, simple and cost-effective alternative to currently marketed sampling devices. In addition, the device will meet the sample collection needs of potential customers who are seeking an alternative to blood testing but still prefer the advantages of high volume batch testing provided by traditional diagnostic methods such as EIA," stated Roger I. Gale, Calypte's President and CEO. "Aware Messenger(TM) is consistent with our growing product line which is aimed at improving the ease with which sample collection and testing can occur." Calypte Biomedical currently markets several diagnostic tests for HIV under the Aware(TM) brand outside the U.S. including its Aware(TM) HIV-1/2 OMT rapid oral fluid test.
According to Dr. Ronald W. Mink, Calypte's Chief Science Officer, "This product provides an exciting new opportunity for Calypte in the laboratory based diagnostics business. The Aware Messenger(TM) sample buffer is specifically formulated to promote sample stability and compatibility with the widest range of clinical laboratory tests. We believe that our tasteless swab, pre-designed for compatibility with conventional clinical assays, and providing a speedy collection without the need for additional processing at the laboratory, constitutes a significant competitive advantage in the oral specimen collector market. Further, we anticipate that users will find Aware Messenger(TM) to be ideally suited for the collection of oral fluid specimens containing antibodies and analytes of interest and will find that it provides excellent specimen stability, even at non-refrigerated temperatures. The design of the Aware Messenger(TM) product provides great potential for current and future expansion into diagnostic product opportunities in the U.S. and international markets."
The Aware Messenger(TM) oral fluid sample collection device uses an untreated, soft, tasteless swab and takes only 15-20 seconds to collect a sample rich in oral mucosal transudate. The device yields a large quantity of sample that is ready for testing without additional processing by the testing laboratory either immediately upon receipt or at a later time at a remote testing laboratory.
Collecting a sample with the Aware Messenger(TM) device involves a simple back and forth wipe of the upper and lower gum line with a swab, which is then placed into a buffer tube. The swab is expressed into the tube and discarded immediately after use. The tube containing the sample can then be delivered to the laboratory where the sample can be immediately and directly used in a suitably validated assay without processing, or stored for batch testing at a later time.
The current device is generic and will require validation by the user for each individual application for diagnostic use by the laboratory. A constantly growing body of literature supports the use of oral fluid specimens as an accurate alternative to blood for the testing for antibodies, antigens, drugs, and genetic testing. Aware Messenger(TM) will be available for shipment in February 2008 in boxes of 50 devices. Additional information about Aware Messenger(TM) can be found on Calypte's website (http://www.calypte.com).
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
Optionen
| Antwort einfügen |
| Boardmail an "Sylvia" |
|
Wertpapier:
Calypte Biomedical
|
0
mann, mann, mann, mann...du meinst wohl eher "täuscht"...muhahahahahahaa war aber abzusehen dieser verlauf. irgendwann wird der konsequente und permanente beschiß am shareholder eben entsprechend quittiert...
152. Es wird still um Calypte... sertralin19 14.02.08 19:38
... das deucht mich fast, ein Kaufsignal zu sehen...
Optionen
0
Approval Enables Manufacturing, Marketing, Distribution and Sales
throughout China
Company to Hold Conference Call at 10:30 a.m. EDT Today to Discuss
Developments
PORTLAND, Ore.--(BUSINESS WIRE)--April 17, 2008--Calypte Biomedical Corporation (OTCBB:CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that its Chinese subsidiary, Beijing Marr Bio-Pharmaceutical Co. Ltd. ("Beijing Marr"), has received registration and marketing approval for Calypte's Aware(TM) HIV-1/2 OMT (oral fluid) rapid test from the State Food and Drug Administration ("SFDA") of China. This approval makes the Aware(TM) HIV-1/2 OMT test the first and only SFDA approved rapid oral fluid HIV test in China.
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "This is a major accomplishment for Calypte and we are thrilled to have received this long awaited approval which permits us to begin actively marketing our rapid diagnostic tests in China, one of the potentially largest HIV testing markets in the world. With the medical devices manufacturing permit received earlier this year, our Beijing Marr subsidiary is now able to manufacture, market, distribute and sell the Aware(TM) HIV-1/2 OMT test throughout the Peoples' Republic of China. China is committed to aggressively tackle the spread of its HIV epidemic and we believe that our Aware(TM) HIV-1/2 OMT (oral fluid) test can and will make a significant contribution to that effort. We appreciate the patience of those investors who have supported us through the long SFDA approval process, particularly our joint venture partners, the Marr Group." Mr. Gale added, "This approval also gives us, for the first time, a very valuable approval in the country of manufacture. Absence of this approval in the past has hampered our ability to register and market the test in a number of countries, a hurdle we can now overcome by producing the domestically approved Aware(TM) product in our Chinese factory. With this SFDA approval, we are now in a position to market and sell in countries representing a total population of nearly 3.7 billion, or over half of the worlds' population."
Dr. Ronald Mink, Chief Science Officer for Calypte, remarked, "This approval has validated our perseverance in pursuing the registration of a product in which we have long had confidence. The transformation of the SFDA over the past two to three years into a first tier agency matching the rigor and integrity of its U.S. and European counterparts resulted in a very thorough review of the Aware(TM) HIV-1/2 OMT (oral fluid) test. We believe that the Chinese authorities are now comfortable with this new technology, which expands the scope of testing platforms currently available in China. The SFDA's restructuring has resulted in a review process and timetable that is similar to what we see in the U.S. FDA. We believe these changes will benefit not only China, by setting a higher standard for new medical products, but will also benefit us, by setting a higher barrier to market entry for would-be competitors. Throughout the entire review process, we received continually positive feedback from the SFDA and we have been confident that our technology is solid and our registration would prevail."
David Harris, Beijing Marr's Chief Executive Officer, stated, "This is a very exciting moment for those of us at Beijing Marr who have worked very hard to gain this approval and ready the factory for manufacture, sale and distribution of the Aware(TM) HIV-1/2 OMT test. We have already received numerous inquiries from HIV program managers and scientists eager to use the product here in China. We now plan to ramp up our production capacity as we build our distribution network to fully realize the market potential of the Aware(TM) HIV-1/2 OMT test in China. Beijing Marr is committed to, and enthusiastic about, bringing this exciting new technology to the Chinese medical community."
Calypte operates in China through Beijing Marr, a joint venture between Calypte and the Marr Group established to manufacture Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and international markets. Beijing Marr operates an ISO 13485:2003 certified manufacturing facility on the outskirts of Beijing. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable to that of U.S. FDA approved blood based laboratory HIV EIA tests.
Conference Call:
Calypte will host a conference call today at 10:30 a.m. EDT. The call can be accessed in the U.S. by dialing 866-510-0707 and outside of the U.S. by dialing 617-597-5376. The participant pass code is 49798845. The conference call will also be webcast live at www.calypte.com. An audio replay of the call will be available through May 18, 2008, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the U.S., or 617-801-6888 from outside of the U.S. The pass code for the playback is 64031187. The web cast will also be available for replay on Calypte's website.
About Calypte Biomedical:
Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
About The Marr Group:
The Marr Group is a private group of companies having a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2007 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance
jdotson@calypte.com
or
CEOcast, Inc.
Investor Relations
Dan Schustack, 212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
Optionen
| Antwort einfügen |
| Boardmail an "Sylvia" |
|
Wertpapier:
Calypte Biomedical
|
0
irgend etwas verkauft? Leider nicht oder? warum ist das so?
Optionen
| Antwort einfügen |
| Boardmail an "Pate100" |
|
Wertpapier:
Calypte Biomedical
|
0
0
PORTLAND, Ore.--(BUSINESS WIRE)--May 29, 2008--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today announced the launch of a new product line, Calypte Life Sciences. Calypte Life Sciences offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers and institutions seeking to develop and optimize immunodiagnostic assay systems. Calypte Life Sciences products are being distributed through a new on-line catalog (www.calyptelifesciences.com) as well as through Calypte's established worldwide network of distributors.
Roger I. Gale, Calypte's President and Chief Executive Officer, stated, "Calypte Life Sciences is a natural extension of what we already do and an important addition to our business, representing another potential revenue stream. Research & Development is one of the strengths of Calypte. We have, among our scientists, a tremendous reservoir of knowledge and experience and they are continuously coming up with novel approaches to solving some very difficult problems commonly encountered by assay developers. The Life Sciences catalog provides a further means by which we can capitalize on our R&D investment and bring new products to market quite quickly. Our Life Sciences division will serve the needs of a large and diverse group of customers that includes universities, governmental organizations, and private companies focusing primarily on assay development. It is particularly exciting that a significant portion of the market is based right here in the U.S."
Dr. Ronald Mink, Calypte's Chief Science Officer, stated that, "The products featured in our Life Sciences catalog are based mostly on technologies that we developed for our core diagnostics business. Many are truly unique. Our Gold Conjugate Clearant, which is currently featured on the home page of our on-line catalog, is one example of such a technology. It helps to reduce the amount of background color 'noise' on membrane-based rapid tests thereby improving their clinical performance. This is just one example and we have many more unique products that can help to improve the performance of diagnostic assays of all types. Through our Life Sciences catalog we are making these products broadly available to researchers and creating additional opportunities for developing better, faster and more cost effective diagnostic products."
Christopher P. Kafka, Vice President of Business Development, stated, "We have been testing the market to evaluate our products and to receive feedback on our new on-line catalog. I am happy to say that the response we have received leading up to our formal launch has been very positive. We have already seen our first sales and in the coming months we plan to aggressively promote our new Life Sciences offerings at major conferences such as the general meeting of the American Society for Microbiology (ASM) in early June, and the annual meeting of the American Association for Clinical Chemistry (AACC) in late July, as well as through online and print media."
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by managements. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2007 and relate to our ability to obtain sufficient financing, if and as needed, and access funds from our existing financing arrangements, in order to continue our current and future operations, and whether demand for our test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
CONTACT: Company:
Calypte Biomedical Corporation
Jerrold D. Dotson, VP-Finance
503-726-2227
jdotson@calypte.com
or
Investor Relations:
CEOcast, Inc.
Dan Schustack
212-732-4300
dschustack@ceocast.com
SOURCE: Calypte Biomedical Corporation
Optionen
| Antwort einfügen |
| Boardmail an "kague" |
|
Wertpapier:
Calypte Biomedical
|
0
Calypte Biomedical Corporation Receives Large Order for Aware Diagnostic Test from Middle Eastern Distributor
New Sales Initiative Beginning to Yield Results
PORTLAND, Ore.--(BUSINESS WIRE)--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that it has received an order for 50,000 tests of its Aware™ HIV-1/2 OMT product from LifeLine Scientific, its newly appointed distributor for the UAE and several other countries in the region. The purchase is the first large order resulting from a newly implemented sales initiative.
Donald Taylor, Calypte’s President and Chief Executive Officer, stated, “I am delighted to announce that our local office in Dubai has signed such a significant order LifeLine Scientific is affiliated with a leading provider of healthcare in Abu Dhabi and has direct access to an expansive network of hospitals and pharmacies through which it plans to distribute Calypte’s oral fluid HIV tests.”
Mr. Taylor continued, “This order is the first result of our new sales initiative and reflects the hard work and commitment shown by our people around the world. It also shows the growing market acceptance of our Aware™ HIV-1/2 OMT product. While testing with oral fluid is clearly preferred by patients, easier to do, and safer than testing with blood, it has, nonetheless, faced significant adoption hurdles. As this UAE order demonstrates, we are on the right track and beginning to make headway. We are working hard in Africa, the Middle East, India and numerous other countries around the world to close more deals and build on the momentum we are gaining.”
Mr. Taylor concluded, “I have been on board for just over three months with a clear mission. This is the firststep in our primary objective to increase sales of our products worldwide. I am looking forward to many others in the months and years to come.”
Calypte will begin production as soon as the purchaser’s irrevocable letter of credit is approved.
About Calypte Biomedical Corporation:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware™ HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. For more information, visit www.calypte.com.
Optionen
| Antwort einfügen |
| Boardmail an "kinu" |
|
Wertpapier:
Calypte Biomedical
|
0
1
der Vorstand ist so besoffen in den letzten Tagen gewesen
dass
die sich an der Börse haben eintragen lassen
und
mit sämtlichen Kapital
haben
die sich eintragen lassen
VH
voll da
die Sekretärin durchgevögelt
und
entlassen
der Laden ist komplett abgemeldet
und
lebt jetzt vom Geld der Aktiengeschäfte
20 USD !!!
in nur 3 Wochen !!!
MfG Buran
Optionen
| Antwort einfügen |
| Boardmail an "buran" |
|
Wertpapier:
Calypte Biomedical
|